BofA/Merrill Lynch Downgrades Novartis (NVS) to Underperform
NVS Hot Sheet
Rating Summary:3 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
BofA/Merrill Lynch downgraded Novartis (NYSE: NVS) from Neutral to Underperform.
For an analyst ratings summary and ratings history on Novartis click here. For more ratings news on Novartis click here.
Shares of Novartis closed at $55.72 yesterday, with a 52 week range of $51.60-$64.81.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Novartis click here. For more ratings news on Novartis click here.
Shares of Novartis closed at $55.72 yesterday, with a 52 week range of $51.60-$64.81.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Wedbush Downgrades Maxwell Technologies (MXWL) to Neutral; Elevated Competitive and Supply Chain Risks
- Physicians Office Resource Appoints New Senior Vice President of Business Development
Create E-mail Alert Related Categories
DowngradesRelated Entities
Merrill Lynch, Bank of AmericaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
